PG
PCRX icon

Pendal Group’s Pacira BioSciences PCRX Stock Holding History

Pendal Group’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-22,575
Closed -$859K – 490
2019
Q3 		$859K Sell
22,575
-1,799
-7% -$71.8K 0.01% 295
2019
Q2 		$1.06M Buy
24,374
+1,272
+6% +$54K 0.01% 272
2019
Q1 		$879K Hold
23,102
– – 0.01% 313
2018
Q4 		$994K Sell
23,102
-224
-1% -$10.5K 0.02% 268
2018
Q3 		$1.15M Hold
23,326
– – 0.02% 280
2018
Q2 		$748K Buy
23,326
+1,975
+9% +$68.2K 0.01% 336
2018
Q1 		$665K Buy
21,351
+286
+1% +$10.2K 0.01% 359
2017
Q4 		$962K Buy
21,065
+361
+2% +$14.3K 0.01% 306
2017
Q3 		$777K Buy
20,704
+8,196
+66% +$330K 0.01% 344
2017
Q2 		$597K Buy
+12,508
New +$580K 0.01% 347

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return